Immix Biopharma | Investor Presentation Deck | 64 slides · page 43 of 64
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.
Deck · appendix_data · analyze_data · balanced density
Slide locked Sign in to view
Slide schematic 3/3
source-note 1/1 table 1/1 title 1/1
Components 3
source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.